字号·· | 护眼
卫报

研究表明:模仿伟哥作用的药丸可使阿尔茨海默病进展放缓近三分之一Pill that mimics Viagra can slow Alzheimer’s progression, study suggests

点「原文对照」整页切到原文,或双击某段只看那段的原文。

脑部扫描对比阿尔茨海默病患者病例的代谢模式。AR1001试验的结果显示,它将衰退速度减缓了31%。摄影:丹尼斯·巴利布斯/路透社Brain scans comparing metabolic patterns in Alzheimer’s patient cases. The findings from the AR1001 trials showed it slowed decline by 31%. Photograph: Denis Balibouse/Reuters

一项全球研究表明,一种通过放松血管、增加脑部血流来模仿伟哥作用的药丸,可使阿尔茨海默病患者的认知衰退速度减缓近三分之一。

A pill that mimics Viagra by relaxing blood vessels and increasing blood flow to the brain can slow cognitive decline in people with Alzheimer's disease by almost a third, a global study suggests.

阿尔茨海默病是最常见的痴呆症类型,预计到2050年将影响全球1.53亿人。目前尚无治愈方法。

Alzheimer's is the most common form of dementia, a condition that is forecast to affect 153 million people worldwide by 2050. There is currently no cure.

在一项横跨13个国家(包括英国)的三期临床试验中,研究人员发现,药片AR1001使未接受其他治疗的早期阿尔茨海默病患者的衰退速度减缓了31%。

In a stage three trial spanning 13 countries, including the UK, researchers found the tablet AR1001 slowed decline by 31% in patients with early Alzheimer's disease not receiving any other treatment.

未参与该研究的专家呼吁保持谨慎,但表示结果“令人振奋”且“非常有希望”,可能预示着一种“全新的阿尔茨海默病治疗方法”即将问世。研究结果在波士顿举行的阿尔茨海默病临床试验大会上公布。

Experts not involved with the study urged caution but said the results were "exciting" and "very promising" and could signal the arrival of a "totally new treatment" for Alzheimer's. The findings were presented at the Clinical Trials on Alzheimer's Disease conference in Boston.

AR1001是一种磷酸二酯酶-5抑制剂,属于与伟哥同一药物家族,伟哥用于治疗勃起功能障碍。

AR1001 is a phosphodiesterase-5 inhibitor and from the same family of medicines as Viagra, which is used to treat erectile dysfunction.

韩国公司AriBio生产AR1001,该公司表示,在604名未服用其他阿尔茨海默病药物的患者中,该药物减缓了病情衰退。在服用其他药物的更广泛患者群体中,该药片未达到统计学显著性结果。

The South Korean company AriBio, which makes AR1001, said the drug slowed decline in 604 people taking no other drugs for Alzheimer's. In a wider group of patients taking other drugs, the tablet did not achieve statistically significant results.

爱丁堡大学神经退行性变教授、医学科学院院士Tara Spires-Jones表示,结果看起来“非常有希望”。

Prof Tara Spires-Jones, a professor of neurodegeneration at the University of Edinburgh and a fellow at the Academy of Medical Sciences, said the results looked "very promising".

她说:“这种药物通过增加血流量起作用,很可能还能直接刺激脑细胞中促进学习和记忆的通路。”

"This drug acts through boosting blood flow and likely also directly stimulating pathways in brain cells that promote learning and memory," she said.

英国阿尔茨海默病研究协会研究总监Sheona Scales表示,这些发现“非常令人鼓舞”,标志着“寻找新的阿尔茨海默病治疗方法的重要里程碑”。

Dr Sheona Scales, director of research at Alzheimer's Research UK, said the findings were "very encouraging", and marked "an important milestone in the search for new Alzheimer's treatments".

她表示,AR1001“特别有趣”,因为它是一种口服药物,采取了与现有治疗“不同的方法”。“它不是靶向淀粉样蛋白,而是作用于一种特定酶,并影响参与大脑功能的其他几个过程。”

AR1001 was "especially interesting" because it was an oral drug that took a "different approach" to existing treatments, she said. "Rather than targeting amyloid, it acts on a specific enzyme and influences several other processes involved in brain function.

“试验显示,在未同时服用其他常用阿尔茨海默症药物的参与者中,临床恶化出现了具有统计学意义的减缓。然而,在总体试验人群中,这种获益并不显著。”

"The trial demonstrated a statistically significant slowing of clinical decline in participants who were not taking other commonly used Alzheimer's medications alongside the trial drug. However, this benefit was not significant across the overall trial group.

“尽管如此,这是阿尔茨海默症研究中一个令人鼓舞的进展,并强化了探索不同方法应对这一复杂疾病的重要性。”阿尔茨海默症协会研究与创新副总监理查德·奥克利博士表示:“这些主要结果是一个令人振奋的迹象,表明我们可能会拥有一种全新的早期阿尔茨海默症治疗方法,它针对病因,而不仅仅是症状。

"Nonetheless, this is an encouraging development in Alzheimer's research and reinforces the importance of exploring different approaches to tackling this complex disease." Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: "These topline results are an exciting sign that we could have a totally new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms.

“AR1001采取了一种新颖的方法,通过舒张血管来增加脑部血流量。而且,与其他已在晚期试验中显示出获益的疾病修饰疗法不同,它作为一种每日一片的药片服用,这可能会使治疗更加简单。

"AR1001 takes a novel approach, relaxing blood vessels to increase blood flow to the brain. And unlike other disease-modifying treatments that have shown benefit in late-stage trials, it is taken as a once-a-day tablet, which could make treatment simpler.

“在为期一年的试验中,这种药物能够有效地将人们记忆和思维能力的下降减缓近三分之一,且报告的副作用大多为轻度至中度。”不过,他表示,对于正在服用其他阿尔茨海默症症状治疗药物的人群,该药物似乎效果不如预期,因此需要进一步研究。

"Over the year of the trial, this drug was able to effectively slow down people's decline in memory and thinking by nearly a third, and the side-effects reported were mostly mild to moderate." However, the drug did not seem to be as effective for people taking other drugs for Alzheimer's symptoms, so this needed further investigation, he said.

奥克利说:“AR1001属于与伟哥同一类药物,但它是专门为阿尔茨海默症开发的。”他补充说,人们不应服用伟哥来尝试治疗阿尔茨海默症。

"AR1001 is from the same family of medicines as Viagra, but it is being developed specifically for Alzheimer's disease," said Oakley, adding that people should not take Viagra to try to treat Alzheimer's.

所有专家都呼吁进行进一步试验,并表示,在AR1001能被处方用于治疗阿尔茨海默症之前,必须经过科学界和药品监管机构的审查。

All the experts called for further trials, and said AR1001 would have to be scrutinised by the scientific community and drug regulatory bodies before it could be prescribed to treat Alzheimer's.

阅读媒体原文 ↗